HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tosoni, A. Articles by Brandes, A. A. Search for Related Content PubMed PubMed Citation Articles by Tosoni, A. Articles by Brandes, A. A. Related Collections All Oncology Primary brain tumor Chemotherapy-tumor

Is protracted low-dose temozolomide feasible in glioma patients?

From the Departments of Medical Oncology (A.T., L.P., V.B., A.A.B.), Neurological Sciences (E.M.), and Pathology (M.G.), University Hospital of Padova; Department of Medical Oncology (G.C., L.S., E.F.), Bellaria Hospital, Bologna; and Department of Pathology (C.G.), Verona Hospital, Italy.

Address correspondence and reprint requests to Dr. Alba A. Brandes, Department of Medical Oncology, Azienda Ospedale-Università, Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy; e-mail: aabrandes{at}unipd.it

The authors investigated the safety of 75 mg/m² temozolomide for 21 days every 28 days in glioma patients. This schedule could lead to DNA repair enzyme O⁶-alkylguanine-DNA alkyltransferase depletion, contributing to overcoming drug resistance. Although Phase III studies are forthcoming, no data are available on the long-term toxicity of temozolomide, which, in this series, incurred prolonged, cumulative lymphopenia, which leads to a high incidence of infections.

Disclosure: Dr. Brandes has had an advisory role with Schering-Plough. The remaining authors report no conflicts of interest.

Presented in part at the Poster Session of the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, May 13 through 17, 2005.

Received July 14, 2005. Accepted in final form October 25, 2005.

This article has been cited by other articles:

				S. Kesari, D. Schiff, J. Drappatz, D. LaFrankie, L. Doherty, E. A. Macklin, A. Muzikansky, S. Santagata, K. L. Ligon, A. D. Norden, et al. Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults Clin. Cancer Res., January 1, 2009; 15(1): 330 - 337. [Abstract] [Full Text] [PDF]

				B. Neyns, S. Cordera, E. Joosens, and P. Nader Non-Hodgkin's Lymphoma in Patients With Glioma Treated With Temozolomide J. Clin. Oncol., September 20, 2008; 26(27): 4518 - 4519. [Full Text] [PDF]

				M. E. Hegi, L. Liu, J. G. Herman, R. Stupp, W. Wick, M. Weller, M. P. Mehta, and M. R. Gilbert Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity J. Clin. Oncol., September 1, 2008; 26(25): 4189 - 4199. [Abstract] [Full Text] [PDF]

				A. Wick, J. Felsberg, J. P. Steinbach, U. Herrlinger, M. Platten, B. Blaschke, R. Meyermann, G. Reifenberger, M. Weller, and W. Wick Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma J. Clin. Oncol., August 1, 2007; 25(22): 3357 - 3361. [Abstract] [Full Text] [PDF]

				Q. Zhou, P. Guo, X. Wang, S. Nuthalapati, and J. M. Gallo Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Metronomic and Conventional Temozolomide Dosing Regimens J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 265 - 275. [Abstract] [Full Text] [PDF]

				E. T. Wong, A. A. Brandes, and A. Tosoni Is protracted low-dose temozolomide feasible in glioma patients? Neurology, August 8, 2006; 67(3): 543 - 544. [Full Text] [PDF]

Correspondence: